CARACTERISTICAS CLINICAS Y TRATAMIENTO DEL LINFOMA PRIMITIVO DEL SISTEMA NERVIOSO CENTRAL EN PACIENTES IMMUNOCOMPETENTES

Translated title of the contribution: Primary central nervous system lymphoma: Clinical characteristics and therapeutic management

Research output: Contribution to journalArticle

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare neoplasm but its incidence is increasing among immunocompetent and immunodeficient individuals. The peak of incidence occurs in the 6th and 7th decades in immunocompetent patients. Most patients present with symptoms of expansive cerebral mass. PCNSL can localise in brain, meninx, eyes and spinal cord. Generally, it is a B-cell monoclonal lymphoma of intermediate- or high-grade. PCNSL has a rapid growth, generally limited to CNS. Despite the high complete response rate obtained with conventional treatment (i.e. radiotherapy and corticosteroids), 80% of patients relapse within the first year of follow-up. Optimal radiotherapy seems to consist of whole brain irradiation with 45-50 Gy plus a boost with 10-15 Gy to the bulky area. Chemotherapy significantly improved the therapeutic outcomes. Any immunocompetent patient with PCNSL may be treated with a combined medality that include an initial chemotherapy followed by adequate radiotherapy. The salvage therapy seems to prolong the survival of relapsed patients.

Original languageSpanish
Pages (from-to)44-61
Number of pages18
JournalOncologia
Volume18
Issue number4
Publication statusPublished - 1995

Fingerprint

Lymphoma
Central Nervous System
Radiotherapy
Therapeutics
Drug Therapy
Meninges
Salvage Therapy
Incidence
Brain
B-Cell Lymphoma
Spinal Cord
Adrenal Cortex Hormones
Recurrence
Survival
Growth
Neoplasms

Keywords

  • brain neoplasms
  • chemotherapy
  • combined treatment modality
  • non-Hodgkin's lymphoma
  • primary central nervous system lymphoma
  • radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

@article{a745000e3a2e4774b8df28761a86b463,
title = "CARACTERISTICAS CLINICAS Y TRATAMIENTO DEL LINFOMA PRIMITIVO DEL SISTEMA NERVIOSO CENTRAL EN PACIENTES IMMUNOCOMPETENTES",
abstract = "Primary central nervous system lymphoma (PCNSL) is a rare neoplasm but its incidence is increasing among immunocompetent and immunodeficient individuals. The peak of incidence occurs in the 6th and 7th decades in immunocompetent patients. Most patients present with symptoms of expansive cerebral mass. PCNSL can localise in brain, meninx, eyes and spinal cord. Generally, it is a B-cell monoclonal lymphoma of intermediate- or high-grade. PCNSL has a rapid growth, generally limited to CNS. Despite the high complete response rate obtained with conventional treatment (i.e. radiotherapy and corticosteroids), 80{\%} of patients relapse within the first year of follow-up. Optimal radiotherapy seems to consist of whole brain irradiation with 45-50 Gy plus a boost with 10-15 Gy to the bulky area. Chemotherapy significantly improved the therapeutic outcomes. Any immunocompetent patient with PCNSL may be treated with a combined medality that include an initial chemotherapy followed by adequate radiotherapy. The salvage therapy seems to prolong the survival of relapsed patients.",
keywords = "brain neoplasms, chemotherapy, combined treatment modality, non-Hodgkin's lymphoma, primary central nervous system lymphoma, radiotherapy",
author = "Ferreri, {A. J M} and M. Reni",
year = "1995",
language = "Spagnolo",
volume = "18",
pages = "44--61",
journal = "Oncologia",
issn = "0378-4835",
publisher = "Fundacion Alimentacion Saludable",
number = "4",

}

TY - JOUR

T1 - CARACTERISTICAS CLINICAS Y TRATAMIENTO DEL LINFOMA PRIMITIVO DEL SISTEMA NERVIOSO CENTRAL EN PACIENTES IMMUNOCOMPETENTES

AU - Ferreri, A. J M

AU - Reni, M.

PY - 1995

Y1 - 1995

N2 - Primary central nervous system lymphoma (PCNSL) is a rare neoplasm but its incidence is increasing among immunocompetent and immunodeficient individuals. The peak of incidence occurs in the 6th and 7th decades in immunocompetent patients. Most patients present with symptoms of expansive cerebral mass. PCNSL can localise in brain, meninx, eyes and spinal cord. Generally, it is a B-cell monoclonal lymphoma of intermediate- or high-grade. PCNSL has a rapid growth, generally limited to CNS. Despite the high complete response rate obtained with conventional treatment (i.e. radiotherapy and corticosteroids), 80% of patients relapse within the first year of follow-up. Optimal radiotherapy seems to consist of whole brain irradiation with 45-50 Gy plus a boost with 10-15 Gy to the bulky area. Chemotherapy significantly improved the therapeutic outcomes. Any immunocompetent patient with PCNSL may be treated with a combined medality that include an initial chemotherapy followed by adequate radiotherapy. The salvage therapy seems to prolong the survival of relapsed patients.

AB - Primary central nervous system lymphoma (PCNSL) is a rare neoplasm but its incidence is increasing among immunocompetent and immunodeficient individuals. The peak of incidence occurs in the 6th and 7th decades in immunocompetent patients. Most patients present with symptoms of expansive cerebral mass. PCNSL can localise in brain, meninx, eyes and spinal cord. Generally, it is a B-cell monoclonal lymphoma of intermediate- or high-grade. PCNSL has a rapid growth, generally limited to CNS. Despite the high complete response rate obtained with conventional treatment (i.e. radiotherapy and corticosteroids), 80% of patients relapse within the first year of follow-up. Optimal radiotherapy seems to consist of whole brain irradiation with 45-50 Gy plus a boost with 10-15 Gy to the bulky area. Chemotherapy significantly improved the therapeutic outcomes. Any immunocompetent patient with PCNSL may be treated with a combined medality that include an initial chemotherapy followed by adequate radiotherapy. The salvage therapy seems to prolong the survival of relapsed patients.

KW - brain neoplasms

KW - chemotherapy

KW - combined treatment modality

KW - non-Hodgkin's lymphoma

KW - primary central nervous system lymphoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029038034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029038034&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0029038034

VL - 18

SP - 44

EP - 61

JO - Oncologia

JF - Oncologia

SN - 0378-4835

IS - 4

ER -